Editorial
DIAMOND study: an additional evidence of the interest of being proactive in IBD
Abstract
The DIAMOND study is a multicenter, randomized, open-label study comparing adalimumab (ADA) with ADA plus azathioprine (AZA) in immunosuppressant-naïve CD patients (1).
